Quest Diagnostics plans to acquire Canada-based community laboratory provider LifeLabs in a deal worth nearly $1 billion. Under the agreement announced July 3, the Secaucus-headquartered testing ...

Quest Diagnostics will soon begin offering a new blood-based in-vitro diagnostic test for Alzheimer’s. The disease affects nearly 7 million Americans. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma ...

Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...

By Sahil Pandey April 21 (Reuters) - Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street estimates, citing resilient ...

In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and ...

With demand for COVID-19 tests rapidly drying up, testmakers like Quest Diagnostics are scrambling to find deeper waters that’ll keep them from running aground. Quest, for one, is banking on its core ...

Quest Diagnostics is rated a Buy driven by demographic tailwinds, improving reimbursement, and disciplined capital returns.

But even Labcorp and Quest have limits to how many test machines they can afford. As publicly traded companies that must return profits to shareholders, they can’t invest tens of millions of dollars ...

LOS ANGELES (Reuters) - Quest Diagnostics Inc's molecular test for identifying patients infected with the H1N1 flu virus has been approved by European regulators and is available for distribution to ...